A.F.L.–A.G.C. Building Trades Welfare Plan

Profile: A.F.L.–A.G.C. Building Trades Welfare Plan

Company overview. The A.F. of L.–A.G.C. Building Trades Welfare Plan (also styled AFL-AGC Building Trades Welfare Plan; IRS records list the related "Building Trades AFL-AGC Welfare Fund," EIN 63-0327100) is not a commercial company but a Taft-Hartley multi-employer employee welfare benefit plan — a trust organized under ERISA and classified by the IRS as a 501(c)(9) voluntary employees' beneficiary association. Its office is at 801 St. Francis Street (mailing address P.O. Box 1492), Mobile, Alabama, and its IRS exemption dates to February 1955. As a VEBA it has no public ticker and no parent company; it is an independent labor-management trust governed by union and employer trustees. IRS Form 990 data (fiscal year ending June 2021) shows roughly six employees, about $14.4 million in revenue, and net assets near $20–33 million.

Products / services / operations. The fund administers health and welfare benefits — principally health claims paid on behalf of participants and their dependents — for unionized construction workers in the Mobile, Alabama area. Participating locals include Ironworkers Local 798 and Local 92, Operating Engineers Local 653, Millwrights Local 1192, and Carpenters Local 318 and 1846. It holds no patents and produces no products; it is a benefits payer, not an NPE or patent licensor.

Patent-litigation posture. The tracked data show exactly one case, in which the plan is plaintiff and zero in which it is defendant. That profile does not fit either the operating-company or the NPE pattern — the plan is a purchaser/payor plaintiff asserting no patents. Its lone case was filed July 31, 2020 in the Southern District of New York, not in a patent-heavy venue such as the Eastern District of Texas.

Notable cases. The tracked matter, A.F.L.–A.G.C. Building Trades Welfare Plan v. Jazz Pharmaceuticals, is an indirect-purchaser antitrust suit over the narcolepsy drug Xyrem (sodium oxybate), alleging pay-for-delay patent settlements delayed generic entry. It was consolidated into In re Xyrem (Sodium Oxybate) Antitrust Litigation, MDL No. 2966 (N.D. Cal.), where the plan is a class representative. Jazz agreed to a $145 million class settlement in April 2025, with Hikma adding $50 million; final approval was reported in October 2025.